Alefacept Biosimilar – Anti-CD2 fusion protein – Research Grade

Alefacept Biosimilar – Anti-CD2 Fusion Protein – Research Grade Alefacept Biosimilar – Anti-CD2 Fusion Protein – Research Grade Introduction

Alefacept Biosimilar is a novel therapeutic protein that has been developed as a biosimilar to the original drug, Alefacept. It is an anti-CD2 fusion protein that has been designed to target and treat inflammatory diseases, particularly those involving the immune system. In this article, we will explore the structure, activity, and application of Alefacept Biosimilar in more detail.

Structure of Alefacept Biosimilar

Alefacept Biosimilar is a fusion protein made up of two components – the extracellular domain of human CD2 and the Fc region of human IgG1 antibody. The extracellular domain of CD2 is responsible for binding to its target, while the Fc region of IgG1 provides stability and prolongs the half-life of the protein in the body.

The structure of Alefacept Biosimilar is similar to that of the original drug, Alefacept, which is a fusion protein of the extracellular domain of CD2 and the Fc region of human IgG1. However, Alefacept Biosimilar has been developed using advanced biotechnology techniques, resulting in a highly pure and stable protein.

Activity of Alefacept Biosimilar

Alefacept Biosimilar works by targeting and binding to CD2, a protein found on the surface of T cells. CD2 is involved in the activation and proliferation of T cells, which play a crucial role in the immune response. By binding to CD2, Alefacept Biosimilar blocks the interaction between CD2 and its ligand, preventing the activation and proliferation of T cells.

This activity of Alefacept Biosimilar helps to reduce the inflammatory response in diseases such as psoriasis, rheumatoid arthritis, and multiple sclerosis. In these conditions, the immune system is overactive, leading to inflammation and tissue damage. By inhibiting the activation of T cells, Alefacept Biosimilar helps to control the immune response and alleviate the symptoms of these diseases.

Application of Alefacept Biosimilar

Alefacept Biosimilar is currently being studied for its potential use in the treatment of various inflammatory diseases, including psoriasis, rheumatoid arthritis, and multiple sclerosis. In clinical trials, it has shown promising results in reducing disease activity and improving symptoms in patients with these conditions.

Alefacept Biosimilar is also being investigated as a potential therapy for other immune-mediated diseases, such as type 1 diabetes and graft-versus-host disease. These diseases involve an abnormal immune response, and Alefacept Biosimilar’s ability to target and regulate T cell activity makes it a promising candidate for treatment.

Conclusion

Alefacept Biosimilar is a novel anti-CD2 fusion protein that has been developed as a biosimilar to the original drug, Alefacept. It works by targeting and inhibiting the activation of T cells, which play a crucial role in the immune response. This activity makes it a potential therapy for various inflammatory and immune-mediated diseases. With ongoing research and clinical trials, Alefacept Biosimilar has the potential to provide a safe and effective treatment option for patients suffering from these conditions.

ProteoGenix catalogue number PX-TA2000. For research use only.

Target: Alefacept Biosimilar – Anti-CD2 fusion protein – Research Grade; Expression system: XtenCHO; Purity: >90% by SDS-PAGE.; Buffer: 0.01M PBS, pH 7.4.; Applications: ELISA, WB.

Available configurations: 50ug, 100ug, 1mg.

Download the manufacturer datasheet